Psilocybin therapy to help you taper opioid pain medicine
Part of Mental health, Pain clinical trials.
This Phase 2 study tests a structured, therapist-led treatment using standardized natural psilocybin to help people reduce or stop long-term opioid use for chronic (non-cancer) pain. It’s mainly for those who have tried tapering before but couldn’t, and who are motivated to try again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 to 75
- You have chronic pain from a non-cancer cause (like nerve pain, fibromyalgia, migraines, back or muscle/joint pain)
- You’ve been on a stable opioid dose for at least 90 straight days
- You’ve tried to taper or stop opioids before and want to try again
- You can swallow capsules or tablets
- If you could become pregnant, you agree to use effective birth control during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether psilocybin (a psychedelic medication) can help people who have both chronic nerve pain and depression that hasn't responded to standard treatments. The goal is to see if it can reduce pain and improve mood.
This study tests whether psilocybin can help people who want to stop using opioids and are already in treatment. Eligible participants receive a single dose of psilocybin in a supervised setting and are followed to see if it reduces opioid use.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This study tests whether psilocybin (a compound found in certain mushrooms), given with therapy, can help people with moderate to severe opioid use disorder reduce their opioid use. Participants must have stable housing and a support person to join.
This study tests whether adding psilocybin (a psychedelic medicine) to buprenorphine (a medication for opioid use disorder) can help people stop using opioids and stay in recovery. It is for people who have already been on buprenorphine but are still using other opioids.
This trial tests whether psilocybin can help people recovering from opioid use disorder while living at a residential treatment center. If you are already taking buprenorphine/naloxone (Suboxone), methadone, or have received Sublocade, this study may be an option for you.
Hear when a new Opioid Dependence trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.